Genetic knockout of SIRT2 in a Huntington's disease mouse model showed no improvement in tubulin acetylation and the progression of neurological pathologies [70], whereas treatment with a SIRT2 inhibitor for up to 14 weeks confers neuroprotection against Huntington's related toxicity [71]. This evidence concerns the gene SIRT2 and juvenile Huntington disease.